



**16TH WORLD CONGRESS OF
BIOLOGICAL PSYCHIATRY**



2024
WORLD CONGRESS
ADVANCE PROGRAM

İSTANBUL, TÜRKİYE

4 JUNE - 8 JUNE 2024

*ISTANBUL LUTFI KIRDAR
INTERNATIONAL
CONVENTION & EXHIBITION
CENTER*





Table of Contents

About WFSBP	3
Agenda at a Glance	4
Plenary Sessions	6
Plenary Debate Sessions	10
Concurrent Symposia	11
WFSBP Awards	15
Conference Planners	16
Sponsors	19




ABOUT WFSBP

HISTORY

Founded in 1974, the World Federation of Societies of Biological Psychiatry is a non-profit worldwide organization comprising 64 National Societies of Biological Psychiatry and individual members representing professionals from over 70 countries. With this multitude of countries represented in its worldwide community, the World Federation has built an international network of opinion leaders, the majority of whom are key opinion leaders in the practice of biological psychiatry.

PURPOSE

- To foster and encourage scientific research and advancement in the field of biological psychiatry
- To improve the quality of training spanning all the biological psychiatry sciences
- To promote education and achieve the highest level of knowledge and understanding within the field
- To provide information and guidance to all institutions, societies, or individuals with an interest in biological psychiatry
- To establish, build, and maintain solid collaboration with international and national organizations related to biological psychiatry





AGENDA AT A GLANCE

Wednesday, 5 June 2024

Pre-Conference Workshops

Concurrent Symposia

Ceremonial Opening & Honorific Awards Session

Opening Plenary

Opening Reception

Thursday, 6 June 2024

Plenary Session

Free Communication/Orals Session

Concurrent Symposia

Poster Session

Concurrent Symposia

Plenary Debate Session

Concurrent Sessions

General Assembly



AGENDA AT A GLANCE

Friday, 7 June 2024

Plenary Session

Free Communication/ Orals Session

Concurrent Symposia

Poster Session

Concurrent Symposia

Plenary Debate Session

Concurrent Workshops

President's Dinner

Saturday, 8 June 2024

Plenary Session

Concurrent Symposia

Plenary Debate Session

Concurrent Symposia



PLENARY SESSION



Reflections on The Future of Psychiatry Drug Discovery

Wednesday, 5 June 2024, 6:30 PM

John Krystal, MD | Yale Department of Psychiatry

Presenter Bio

Dr. Krystal is McNeil Professor and Chair of Psychiatry at Yale and Yale-New Haven Hospital. He studies the neurobiology and treatment of psychiatric disorders. His laboratory discovered the rapid antidepressant effects of ketamine. He directs the Yale Center for Clinical Investigation, Center for the Translational Neuroscience of Alcohol, and Neuroscience Division of the National Center for PTSD. He is a member of the National Academy of Medicine; Fellow of the American Association for the Advancement of Science; co-director of the Neuroscience Forum of the National Academies of Sciences, Engineering, and Medicine; editor of Biological Psychiatry; and co-founder of Freedom Biosciences.

Objective

To review challenges that have traditionally plagued the development of medications for psychiatry indications and to highlight two areas of exciting recent developments: 1) ketamine and psychedelics and 2) antipsychotics that may work via targets other than the dopamine D2 receptor.

PLENARY SESSION



Substance Use and Abuse: Advances in Neurobiology and Treatment of Substance Use Disorders

Thursday, 6 June 2024, 8:00 AM

Nora Volkow, MD | NIDA

Presenter Bio

Nora D. Volkow, M.D., is the Director of the National Institute on Drug Abuse (NIDA), which supports most of the world's research on the health aspects of drug abuse and addiction. Dr. Volkow's scientific research was instrumental in demonstrating that drug addiction is a disease of the human brain and, as NIDA Director, her work has promoted research that improves the prevention and treatment of substance use disorders. As a research psychiatrist, Dr. Volkow pioneered the use of brain imaging to investigate the toxic and addictive effects of abusable drugs. Her studies documented disruption of the dopamine system in addiction with its consequential functional impairment of frontal brain regions involved with motivation, executive function and self-regulation. She has also made important contributions to the neurobiology of obesity, and ADHD and has published more than 920 peer-reviewed articles, written more than 120 book chapters and non-peer-reviewed manuscripts, co-edited a Neuroscience Encyclopedia and edited four books on neuroimaging for mental and addictive disorders.

Objective

Addiction, a complex disorder linking genes, development and the social environment has, for decades, been illuminating our understanding of the human brain and is leading the way toward promising strategies for its effective treatment.

PLENARY SESSION



A New Era in AD Drug Trials: Translating Hope into Impact

Friday, 7 June 2024, 8:00 AM

Catherine Mummery, PhD | University College London

Presenter Bio

Cath Mummery is a consultant neurologist at the National Hospital for Neurology and Neurosurgery. She is chair of the NIHR Dementia Translational Research Collaboration, building a national unified trials network for early phase clinical trials, accelerating dementia translational research in the UK. She is Head of Clinical Trials at the Dementia Research Centre, University College London, and Deputy Director for the Leonard Wolfson Experimental Neurology Centre, a cutting-edge research facility dedicated to the conduct of early phase trials in neurodegeneration. Over the past 17 years, she has been chief investigator on over 20 early phase drug trials of potential disease modifying agents in sporadic Alzheimer's disease (AD) and genetic forms of AD and frontotemporal dementia, with a particular focus on novel mechanisms in first-in-human trials including checkpoint inhibitors, gene silencing and AAV genetic therapies. As clinical lead for the UCL Neurogenetic Therapies Programme, she leads a programme of innovative collaboration between industry and academia to accelerate progress in genetic therapies in dementia. Her driving ambition is to ensure we not only have treatments that can alter the course of neurodegenerative diseases like Alzheimer's, but that we can deliver them promptly, safely and equitably.

Objective

The search for treatments for Alzheimer's disease has been a long and arduous one with many negative trials and heated debate on what we should be targetting, and how. However, recent results on anti amyloid immunotherapies have shown for the first time that we can alter the course of the disease and, while modest, have given us a foundation on which to build.

PLENARY SESSION



Can We Re-Medicalise the Psychedelic Experience?

Saturday, 8 June 2024, 8:00 AM

Guy Goodwin, FRCPPsych | University of Oxford

Presenter Bio

Guy Goodwin is CMO, Compass pathways and Emeritus Professor of Psychiatry at the University of Oxford, UK. His research interests are the treatment of mood disorder and the potential to improve treatment using new technology and new drugs, notably the psychedelics. He is a Fellow of the American College of Neuropsychopharmacology, has previously held the position of President of the British Association for Psychopharmacology and the European College of Neuropsychopharmacology (ECNP).

Objective

Despite the widespread availability of multiple antidepressant treatments, depression remains a common and oftentimes debilitating disorder. A proportion of patients with major depressive disorder fail two or more antidepressant treatments and are considered to have treatment-resistant depression (TRD). Recent attention has turned to psilocybin and other psychedelic compounds as potential rapidly acting and durable episodic treatments for psychiatric disorders including depression.

PLENARY DEBATE SESSIONS



What Has Neuroimaging Done for Biological Psychiatry?

Thursday, 6 June 2024, 3:30 PM

Stephen Lawrie, FRCPsych, MD | University of Edinburgh

Deanna Barch, PhD | Washington University in St. Louis



Polygenic Risk Scores in Psychiatry - Utility or Futility?

Friday, 7 June 2024, 3:30 PM

Evangelos Vassos, MD | King's College London

Ole Andreassen, MD, PhD | University of Oslo



Does Nature Favour Dimensional or Categorical Diagnoses

Saturday, 8 June 2024, 3:30 PM

Anthony Pelosi, MRCPsych | University of Glasgow

Steven Hyman, MA, MD | Harvard University





CONCURRENT SYMPOSIA


Wednesday, 5 June 2024, 4:15 PM

- Revising Construct of Schizophrenia: Relevance to Biological Research
- The Different Faces of Depression across the Life span: From Social Isolation to Suicide
- Predictive Biomarkers and New Methodological Approaches for Mental Disorders
- Biomarkers in Insomnia: Evidence Derived from a WFSBP Task Force Consensus Statement
- Manuscript Writing Workshop

Thursday, 6 June 2024, 9:30 AM

- Understanding Body Dysmorphic Disorder (BDD): Latest International Research
- Social Isolation in Youths: Prevention and Treatment Strategies
- From Damaged DNA to Morbidity: Mitochondrial Dysfunction in Bipolar Disorder as a Novel Therapeutic Target

Thursday, 6 June 2024, 1:30 PM

- Neuroprogression in Psychiatric Disorders: Early detection, Intervention, and Prevention
 - Grant Writing Workshop
 - Exploring Current & Future Directions in the Microbiome – A Focus on Neuropsychiatric Disorders
 - The Art of Prescribing Clozapine: Novel Developments.
 - New Insight and Development of Integrative Treatment in Schizophrenia
- 



CONCURRENT SYMPOSIA

Thursday, 6 June 2024, 3:30 PM

- Dysregulations of Endogenous Amino Acids and Related Neurocircuits in Psychiatric Disorders
- Personalized Treatment of Bipolar Disorder
- Applying Personalized Medicine to Bipolar Disorder
- Innovation in Opioid Agonist Therapy and Withdrawal Management
- Immune-Metabolic Dysfunction in Mental Disorders: An Update on Current Evidence

Thursday, 6 June 2024, 5:00 PM

- International Studies on Brain Maturation and Developmental psychopathology: From Birth to Adulthood
- The Role of Reward System in Psychiatric Disorders: A Transdiagnostic Approach
- Update on Treatment Resistant Depression
- Psychiatric Electrophysiology as Add-On Tool in the Management of Addiction Disorders
- Translating Psychiatric Genetics to Clinical Applications with Novel Statistical and Machine Learning Approaches
- Neuro Science Based Nomenclature

Friday, 7 June 2024, 9:30 AM

- The Role of Dopamine in Bipolar Disorder Mood Cycling and Dysregulated Circadian Cycles: A Dopaminergic Rhythmopathy?
- Potential Clinical Tools Across Psychiatric Disorders: From Biomarkers to Clinical Markers
- Decoding mental disorders - deciphering the genetic basis and exploring animal and iPSC models.



CONCURRENT SYMPOSIA

Friday, 7 June 2024, 1:30 PM

- Autism-Spectrum-Disorder in the Setting of Practical Adult Psychiatry: Clinical Presentation and Therapeutic Approaches
- Oligodendrocyte Pathology and Cognition in Severe Mental Disorders
- Presentation Skills Workshop
- Early Intervention for Bipolar Disorder: From Cutting Edge Science to Transformative Clinical Practice
- Translational Addiction Studies of Novel Psychoactive Substances
- Lifestyle and CAM therapies for wellness and treatment of depressive disorders

Friday, 7 June 2024, 3:30 PM

- Sexual Violence and Women
- Neuropsychiatric Applications of Non-Invasive Brain Stimulation
- WFSBP Task Force Treatment Guidelines Unipolar Depressive Disorders
- Neuro Science Based Nomenclature

Saturday, 8 June 2024, 9:30 AM

- Preventing and Ameliorating Treatment-Resistant depression: Best Practice and beyond
 - Heterogeneity in Psychotic Disorders across Levels of Research
 - GALENOS: A new living evidence resource for research prioritisation in mental health
 - Updates in ECT Practice and Research: New Applications
 - Neuroprogression in Psychiatric Disorders: Biomarkers for Staging and Interventions for Prevention
 - Cognitive Impairment in Bipolar Disorders
- 

CONCURRENT SYMPOSIA

Saturday, 8 June 2024, 1:30 PM

- White Matter in Mental Illness, as a Biomarker and Therapeutic Target
- The Pharmacological Treatment of Eating Disorders: New Guidelines, Insights, and Perspectives
- Tools for Optimizing Pharmacotherapy in psychiatry: Focus on Antipsychotics
- PARAM: A Neurodevelopmental Cohort from India
- Innovations in Pharmacogenomic Research: Translation and Clinical Utility
- Genetic Risk Predictions and Biological Mechanisms in ADHD - Towards Precision Medicine

Saturday, 8 June 2024, 3:30 PM

- When Randomized Trials Aren't an Option: Target Trial Emulation in Psychiatric Research
- Precision Psychiatry Approach for Mood Disorders: Role of Brain Biomarkers and Dysfunctional Immune Response
- Big Data Approaches to Discover Disease Mechanisms of Mental Illness





WFSBP AWARDS



LIFETIME ACHEIVEMENT

Siegfried Kasper

Austria



LIFETIME ACHEIVEMENT

Mary Asberg

Sweden



RESEARCH

Dominique Endres

Germany



EXCELLENCE IN EDUCATION

Rajiv Tandon

United States



RESEARCH

Tadafumi Kato

Japan

EXECUTIVE COMMITTEE



Lakshmi Yatham

President
Canada



Peter Falkai

President-Elect
Germany



Michael Berk

Vice President
Australia



Soraya Seedat

Secretary
South Africa



Frederico Duarte Garcia

Treasurer
Brazil



Oguz Karamustafalioglu

Vice-Secretary
Turkey



Adriana Rivetti

Vice-Treasurer
Argentina



Benicio Frey

Vice-Treasurer
Canada



Daihui Peng

**Honorary Vice-Secretary
Outreach**
People's Republic of China

SCIENTIFIC PROGRAM COMMITTEE MEMBERS

CHAIR: Soraya Seedat

CO-CHAIR: Dost Ongur, M.D.,Ph.D

Mohamed Alsuwaidan

Ole Andreassen, Prof. Dr.

Istvan Bitter, M.D.

Paolo Brambilla, Prof. Dr.

Yu Hai Eric Chen, FRCPsych

Jun Chen, M.D.,Ph.D.

Andrea Cipriani, M.D.,Ph.D.

Deepak D'Souza

Chris Davey

Katharina Domschke Ph.D.,Prof.

Naomi Fineberg

Wolfgang Gaebel

Ishrat Husain, M.D.

Afzal Javed

Tao Li, Prof.

Mario Maj

Samer Makhoul

Ricardo Marcelo Corral

Andrew Nierenberg

Dan Rujescu

Taiwo Sheikh

Rajiv Tandon, M.D.

Florence Thibaut, Prof.,M.D.,Ph.D.

Simavi Vahip

Gang Wang

Allan Young, FRCP,M.D.,Ph.D.

Carlos Zarate, M.D.



REGIONAL ORGANIZING COMMITTEE MEMBERS

Chair: Bilgen Taneli

Co-Chair: Oguz Karamustafalioglu

Secretary: Yesim Taneli

Cengiz Akkaya

Yakup Albayrak

Koksal Alptekin

Kursat Altinbas

S. Mehdi Samimi Ardestani

Kemal Arikan

Murat Ilhan Atagun

Hamdullah Aydin

Yavuz Ayhan

Mansur Beyazyurek

Tezan Bildik

Ali Caykoylu

Deniz Ceylan

Fusun Cetin Cuhadaroglu

Aysen Esen Danaci

Dimitris Dikeos

Murat Demet

Berker Duman

Mehmet Cagdas Eker

Eka Chkonias

Engin Eker

Salih Saygin Eker

Hale Yapici Eser

Kostas N. Fountoulakis

Ali Saffet Gonul

Sinan Guloksuz

Cicek Hocaoglu

Ilkin Icelli

Filiz Izci

Gul Karacetin

Sacit Karamursel

Nesrin Karamustafalioglu

Selcuk Kirli

Emine Eren Kocak

Martina Rojnic Kuman

Nahit Motavalli Mukaddes

Aslan Oguz

Fuat Ozgen

Asli Sarandol

Coskun Sarman

Yusuf Sivrioglu

Constantin R. Soldatos

Haldun Soygur

Sibel Suzen

Suna Taneli

Tolga Taneli

Atilla Tekin

Alp Ucok

Ismail Hakki Ulus

Arif Verimli

Aylin Yazici

Kemal Yazici

Mustafa Yildiz

THANK YOU TO OUR SPONSORS

SPONSORED SYMPOSIA



GEDEON RICHTER

BRONZE SPONSOR



Boehringer
Ingelheim

CONFERENCE SUPPORTER





THANK YOU

CONTACT US :



+1 615.649.3070



info@wfsbp.org



www.wfsbp.org | www.wfsbp-congress.org



5034A Thoroughbred Lane, Brentwood, TN 37027

